Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Atypical antipsychotic (AAP) medications that have revolutionized the treatment of mental illness have become stigmatized by metabolic side effects, including obesity and diabetes. It remains controversial whether the defects are treatment induced or disease related. Although the mechanisms underlying these metabolic defects are not understood, it is assumed that the initiating pathophysiology is weight gain, secondary to centrally mediated increases in appetite. To determine if the AAPs have detrimental metabolic effects independent of weight gain or psychiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healthy subjects (n = 10, each group) under controlled in-patient conditions while maintaining activity levels. Prior to and after the interventions, we conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin sensitivity and glucose disposal. We found that olanzapine, an AAP highly associated with weight gain, causes significant elevations in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon coincident with insulin resistance compared with placebo. Aripiprazole, an AAP considered metabolically sparing, induces insulin resistance but has no effect on postprandial hormones. Importantly, the metabolic changes occur in the absence of weight gain, increases in food intake and hunger, or psychiatric disease, suggesting that AAPs exert direct effects on tissues independent of mechanisms regulating eating behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In psychiatry, iatrogenesis has traditionally been concerned with medical complications of psychotropic drug treatment [3], such as tardive dyskinesia [4] and insulin resistance [5] with antipsychotic drugs, and cardiac and metabolic disturbances with antidepressant medications [6][7][8].”
From Iatrogenic Factors in Psychopathology (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 2×
“Over the past decade, there has been increasing recognition that some of the second-generation antipsychotic medications, termed the atypical antipsychotics (AAPs), are associated with an increased incidence of obesity (1), type 2 diabetes (2,3), and cardiovascular disease (4,5).”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“However, elevations in GLP-1 coincident with insulin resistance and increases in glucagon are surprising since GLP-1 inhibits glucagon release (37) and is attenuated in type 2 diabetes (38).”
BackgroundMcEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140 · cited 1×
“Aripiprazole tends to cause less weight gain than olanzapine (15) and is often considered metabolically neutral (16–18).”
BackgroundAssessment of Insulin Sensitivity in Vivo*
Bergman, R. N., Finegood, D. T., & Ader, M. (1985) · Endocrine Reviews · doi:10.1210/edrv-6-1-45 · Cited by 1,066 · cited 8×
“Preintervention, postprandial glucose levels were not significantly different across treatments (F(2,27) = 0.”
BackgroundResultInfluentialCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 1×
“The implications for public health are tremendous (6) due to the large number of adult patients treated with these agents and the increasing use of off-label prescriptions to children (7) and the elderly (8).”
BackgroundVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“However, elevations in GLP-1 coincident with insulin resistance and increases in glucagon are surprising since GLP-1 inhibits glucagon release (37) and is attenuated in type 2 diabetes (38).”
BackgroundGlucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731 · cited 1×
“Two important variables that will be measured in future studies are glucose-dependent insulinotropic peptide, known to enhance insulin secretion (47), and cortisol, which can induce insulin resistance (48).”
Background
Cited by
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences
Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., & Scarselli, M. (2021) · Pharmaceuticals · doi:10.3390/ph14030238 · Cited by 250
“with compensatory stimulation of the β-cells [63,89].”
Role of endoplasmic reticulum stress in drug‐induced toxicity
Foufelle, F., & Fromenty, B. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.211 · Cited by 246
“However, the pathophysiological significance of this effect remains unclear since this drug classically induces hyperinsulinemia, even in the absence of weight gain (Melkersson and Dahl 2003; Teff et al. 2013).”
BackgroundInteraction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G., & Ellingrod, V. L. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1890 · Cited by 235
“Data suggest that in response to AAPs without increases in BMI, both human and animal models incur metabolic phenotypes such as glucose dysregulation.(27) This makes the decreased relative abundance of A.”
BackgroundThe antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115225 · Cited by 197
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Siafis, S., Tzachanis, D., Samara, M., & Papazisis, G. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170630163616 · Cited by 185
“However, clinical evidence suggests that olanzapine increases both cephalic and postprandial insulin levels, indicating complex and compensatory interactions of central and peripheral muscarinic signaling [51, 114].”
BackgroundSecond-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
Grajales, D., Ferreira, V., & Valverde, Á. M. (2019) · Cells · doi:10.3390/cells8111336 · Cited by 179
“In another study in healthy subjects without psychiatric history and with normal body-mass index, olanzapine or aripiprazole (10 mg/d) were administered for 9 days and insulin sensitivity was evaluated after conducting a meal challenge before and after HEC analysis [49].”
BackgroundMethodDash, S., Syed, Y. A., & Khan, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.880544 · Cited by 171
“Further, administration of olanzapine and aripiprazole for a short duration directly impacts tissue function enhances peripheral insulin resistance, independent of weight gain in healthy people (Teff et al., 2013).”
BackgroundMolecular pathophysiology of metabolic effects of antipsychotic medications
Ballon, J. S., Pajvani, U. B., Freyberg, Z., Leibel, R. L., & Lieberman, J. A. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.07.004 · Cited by 147
Correll, C. U., Newcomer, J. W., Silverman, B. L., DiPetrillo, L., Graham, C. E., Jiang, Y., Du, Y., Simmons, A., Hopkinson, C., McDonnell, D., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19121279 · Cited by 138
Raben, A. T., Marshe, V. S., Chintoh, A., Gorbovskaya, I., Müller, D. J., & Hahn, M. K. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00741 · Cited by 113
“In healthy controls treated with antipsychotics, there is evidence to suggest that OLZ increases serum insulin levels and simultaneously induces peripheral insulin resistance, even prior to any weight gain (Hardy et al., 2007; Teff et al., 2013).”
BackgroundSecond Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor
Weston–Green, K., Huang, X., & Deng, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0115-5 · Cited by 122
“On the other hand, reports of increased acute insulin response following olanzapine administration [46] may suggest that peripheral M3R blockade by olanzapine upregulates central (hypothalamic and brainstem) M3Rs [122], enhancing vagal efferent activity and increasing glucose/post-prandial insulin response, that progr…”
BackgroundMolecular Mechanisms of Antipsychotic Drug-Induced Diabetes
Chen, J., Huang, X.-F., Shao, R., Chen, C., & Deng, C. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00643 · Cited by 98
The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
Bretler, T., Weisberg, H., Koren, O., & Neuman, H. (2019) · BMC Medicine · doi:10.1186/s12916-019-1346-1 · Cited by 104
New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion
Farino, Z. J., Morgenstern, T. J., Maffei, A., Quick, M., Solís, A. J. D., Wiriyasermkul, P., Freyberg, R. J., Aslanoglou, D., Sorisio, D. A., Inbar, B., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0344-6 · Cited by 105
Flowers, S. A., Baxter, N. T., Ward, K. M., Kraal, A. Z., McInnis, M. G., Schmidt, T. M., & Ellingrod, V. L. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2214 · Cited by 100
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
“increases with SGA treatment (290) and is associated with both hyperglycemia as well as insulin resistance (291).”
BackgroundAslanoglou, D., Bertera, S., Sánchez-Soto, M., Benjamin Free, R., Lee, J., Zong, W., Xue, X., Shrestha, S., Brissova, M., Logan, R. W., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01171-z · Cited by 96
Singh, R., Bansal, Y., Medhi, B., & Kuhad, A. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.12.003 · Cited by 96
“Additionally, chronic olanzapine treatment has been found to increase serum glucagon levels in human (Teff et al., 2013) as well as in rats (Smith et al.”
BackgroundThe reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
“A recent study has found that some second-generation antipsychotics (olanzapine and aripiprazole) are associated with insulin resistance independent of weight gain, increase in food intake and presence of a mental disorder [50].”
BackgroundPharmacological treatment for generalized anxiety disorder in adults: an update
Reinhold, J. A., & Rickels, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059424 · Cited by 82
“There is evidence to suggest that AAPs influence glucose sensitivity and induce insulin resistance even after a single dose [24,115].”
BackgroundSelf-citationAtypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies
Burghardt, K. J., Seyoum, B., Mallisho, A., Burghardt, P. R., Kowluru, R. A., & Yi, Z. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.004 · Cited by 95
“Tef f 2013(30) Olanzapine(10)* Aripiprazole(10)* Placebo Randomized, parallel, double-blind, placebocontrolled trial 9-day inpatient interv ention with pre-drug stabilization period Total: 30 Olanzapine: 10 Aripiprazole: 10 Placebo: 10 4 Hy perinsulinemic Eugly cemic Clamp Weight (Kilograms)”
InfluentialAntipsychotics and glucose metabolism: how brain and body collide
Kowalchuk, C., Castellani, L. N., Chintoh, A., Remington, G., Giacca, A., & Hahn, M. K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00164.2018 · Cited by 85
“Presently, only two studies in humans have employed tracer dilution methodology during HIECs examining insulin-induced suppression of endogenous glucose production (98, 103).”
BackgroundResultInfluentialOlanzapine-induced lipid disturbances: A potential mechanism through the gut microbiota-brain axis
Zhu, Z., Gu, Y., Zeng, C., Yang, M., Yu, H., Chen, H., Zhang, B., & Cai, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.897926 · Cited by 100
“Specifically, available evidence shows that altered levels of adenosine 5′-monophosphate-activated protein kinase (AMPK) and gastrointestinal peptide (such as glucagon-like peptide-1, GLP-1) can contribute to the lipid metabolic side effects induced by OLZ (Ikegami et al., 2013; Teff et al., 2013; Li et al., 2016).”
BackgroundNicol, G. E., Yingling, M. D., Flavin, K. S., Schweiger, J. A., Patterson, B. W., Schechtman, K. B., & Newcomer, J. W. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1088 · Cited by 83
Iatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82
Rubin, D. M., Kreider, A. R., Matone, M., Huang, Y.-S., Feudtner, C., Ross, M. E., & Localio, A. R. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2015.0285 · Cited by 77
Ren, L., Zhou, X., Huang, X., Wang, C., & Li, Y. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.12.015 · Cited by 77
Gaspar, H. A., & Breen, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-12325-3 · Cited by 67
Cuerda, C., Velasco, C., Merchán‐Naranjo, J., García-Peris, P., & Arango, C. (2013) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2013.253 · Cited by 70
Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review
D’Alessandro, C., Benedetti, A., Di Paolo, A., Giannese, D., & Cupisti, A. (2022) · Nutrients · doi:10.3390/nu14010212 · Cited by 66
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Stogios, N., Humber, B. E., Agarwal, S. M., & Hahn, M. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01458-0 · Cited by 64
“…in circulating adiponectin levels [44] Insulin - Hormone released by the pancreas that controls glucose regulation - Dopamine blockade in the pancreas increases insulin responses, leading to hyperinsulinemia [45, 46] - Insulin in the periphery is an anabolic hormone and can promote fat storage.”
BackgroundRole of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder
Hershenberg, R., Grös, D. F., & Brawman‐Mintzer, O. (2014) · CNS Drugs · doi:10.1007/s40263-014-0162-6 · Cited by 70
Pisano, S., Catone, G., Veltri, S., Lanzara, V., Pozzi, M., Clementi, E., Iuliano, R., Riccio, M. P., Radice, S., Molteni, M., et al. (2016) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-016-0259-2 · Cited by 67
Castellani, L. N., Costa-Dookhan, K. A., McIntyre, W. B., Wright, D. C., Flowers, S. A., Hahn, M., & Ward, K. M. (2019) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20190013 · Cited by 71
“On the other hand, seven day olanzapine treated was also associated with the development of insulin resistance, despite no change in fasting glucose levels post-treatment [69].”
BackgroundGut microbiota: An intermediary between metabolic syndrome and cognitive deficits in schizophrenia
Zeng, C., Yang, P., Cao, T., Gu, Y., Li, N., Zhang, B., Xu, P., Liu, Y., Luo, Z., & Cai, H. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110097 · Cited by 55
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
“, 2010b) or elevated postprandial GLP-1 levels following olanzapine administration (Teff et al., 2013).”
BackgroundResultInfluentialSteen, V. M., Skrede, S., Polushina, T. V., López, M., Andreassen, O. A., Fernø, J., & Hellard, S. L. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.07.011 · Cited by 52
Glucose metabolism alterations in patients with bipolar disorder
Rosso, G., Cattaneo, A., Zanardini, R., Gennarelli, M., Maina, G., & Bocchio‐Chiavetto, L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.006 · Cited by 50
Srisawasdi, P., Vanwong, N., Hongkaew, Y., Puangpetch, A., Vanavanan, S., Intachak, B., Ngamsamut, N., Limsila, P., Sukasem, C., & Kroll, M. H. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.02.003 · Cited by 49
DIABETIC KETOACIDOSIS ASSOCIATED WITH ANTIPSYCHOTIC DRUGS: CASE REPORTS AND A REVIEW OF LITERATURE
Vuk, A., Kuzman, M. R., Baretić, M., & Osvatić, M. M. (2017) · Psychiatria Danubina · doi:10.24869/psyd.2017.121 · Cited by 50
“Postprandial – acute metabolic hyperinsulinemia and parallel aberrant increase of glucagon coincide with insulin resistance (Melkersson & Jansson 2004, Smith et al. 2008, Teff et al. 2013).”
BackgroundAtypical antipsychotics and effects on feeding: from mice to men
Benarroch, L., Kowalchuk, C., Wilson, V. S., Teo, C., Guenette, M. D., Chintoh, A. F., Nesarajah, Y., Taylor, V. H., Selby, P. L., Fletcher, P. J., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4324-8 · Cited by 46
Kowalchuk, C., Kanagasundaram, P., Belsham, D. D., & Hahn, M. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.01.029 · Cited by 46
Fernø, J., Ersland, K. M., Duus, I. H., González‐García, I., Fossan, K. O., Berge, R. K., Steen, V. M., & Skrede, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.002 · Cited by 43
“However, antipsychotic-induced metabolic adverse effects may also occur independent of weight gain (Albaugh et al., 2011b; Birkenaes et al., 2008; Teff et al., 2013).”
BackgroundNeuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies
Amato, D., Beasley, C. L., Hahn, M., & Vernon, A. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.004 · Cited by 47
Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia
Castellani, L. N., Peppler, W. T., Sutton, C. D., Whitfield, J., Charron, M. J., & Wright, D. C. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.05.005 · Cited by 42
Li, R., Ou, J., Li, L., Yang, Y., Zhao, J., & Wu, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00379 · Cited by 42
“…insulin resistance in this study is parallel with a previous study which demonstrated the existence of hyperinsulinemia and insulin resistance independently from body weight gain and psychiatric disease through the use of olanzapine for 9 days in healthy subjects (Teff et al., 2013).”
ResultKang, S. H., & Lee, J. I. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.2.242 · Cited by 41
Kowalchuk, C., Teo, C., Wilson, V. S., Chintoh, A. F., Lam, L., Agarwal, S. M., Giacca, A., Remington, G. J., & Hahn, M. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.170092 · Cited by 48
Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance
del Campo, A., Bustos, C., Mascayano, C., Acuña‐Castillo, C., Troncoso, R., & Rojo, L. E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00144 · Cited by 39
“org April 2018 | Volume 9 | Article 144 Another confirmation came from a clinical study demonstrating that only 9 days of oral olanzapine treatment causes significant elevations in postprandial insulin, glucagon-like peptide 1, and glucagon coincident with insulin resistance (35).”
BackgroundCardiovascular Safety of Psychiatric Agents: A Cautionary Tale
Manolis, T. A., Manolis, A. S., & Manolis, A. S. (2018) · Angiology · doi:10.1177/0003319718780145 · Cited by 41
Koller, D., Almenara, S., Mejía-Abril, G. P., Saiz‐Rodríguez, M., Zubiaur, P., Román, M. C., Ochoa, D., Navares‐Gómez, M., Santos-Molina, E., Pintos-Sánchez, E., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01566-w · Cited by 40
Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents
Mogwitz, S., Buse, J., Wolff, N., & Roessner, V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00460 · Cited by 40
Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review
Stogios, N., Smith, E., Asgariroozbehani, R., Hamel, L., Gdanski, A., Selby, P. L., Sockalingam, S., Graff‐Guerrero, A., Taylor, V. H., Agarwal, S. M., et al. (2020) · Nutrients · doi:10.3390/nu12123883 · Cited by 38
“8 (PBO) reported in [80] 30% F N/A Hunger/appetite scale (9-point Likert) Food intake weighed (objective) Activity level (number of steps) • Neither medication had a significant effect on weight, subjective hunger/fullness or calorie intake compared to PBO • No significant change in physical activity levels in any gro…”
BackgroundRagguett, R., Hahn, M., Messina, G., Chieffi, S., Monda, M., & Luca, V. D. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2631 · Cited by 37
“, 2007), and three studies examining healthy controls (n = 51; Daurignac, Leonard, & Dubovsky, 2015; Fountaine et al., 2010; Teff et al., 2013).”
BackgroundEffects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism
Sarsenbayeva, A., Marques-Santos, C. M., Thombare, K., Nunzio, G. D., Almby, K. E., Lundqvist, M., Eriksson, J. W., & Pereira, M. J. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104445 · Cited by 41
Guo, C., Liu, J., & Li, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110912 · Cited by 38
A Glimpse into Milestones of Insulin Resistance and an Updated Review of Its Management
Aedh, A. I., Alshahrani, M. S., Huneif, M. A., Pryme, I. F., & Oruch, R. (2023) · Nutrients · doi:10.3390/nu15040921 · Cited by 38
Detecting and Managing Adverse Effects of Antipsychotic Medications
Ames, D., Carr‐Lopez, S. M., Gutierrez, M. A., Pierre, J. M., Rosen, J. A., Shakib, S., & Yudofsky, L. M. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.008 · Cited by 43
Ballon, J. S., Pajvani, U. B., Mayer, L., Freyberg, Z., Freyberg, R. J., Contreras, I., Rosenbaum, M., Leibel, R. L., & Lieberman, J. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754708 · Cited by 37
“(2011), found impaired glucose tolerance after a brief exposure (3 days) to olanzapine, similar to that seen in insulin clamp studies, prior to significant weight gain (Teff et al., 2013).”
Needham, E. J., Humphrey, S. J., Cooke, K. C., Fazakerley, D. J., Duan, X., Parker, B. L., & James, D. E. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.001 · Cited by 35
Kilberg, M. J., Harris, C., Sheikh, S., Stefanovski, D., Cuchel, M., Kubrak, C., Hadjiliadis, D., Rubenstein, R. C., Rickels, M. R., & Kelly, A. T. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa448 · Cited by 34
Self-citationDrug-induced mitochondrial toxicity: Risks of developing glucose handling impairments
Kuretu, A., Arineitwe, C., Mothibe, M. E., Ngubane, P. S., Khathi, A., & Sibiya, N. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1123928 · Cited by 34
Brain insulin action: Implications for the treatment of schizophrenia
Agarwal, S. M., Kowalchuk, C., Castellani, L. N., Costa-Dookhan, K. A., Caravaggio, F., Asgariroozbehani, R., Chintoh, A. F., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.032 · Cited by 34
Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Rickels, K., & Moeller, H. J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1500031 · Cited by 30
“In fact, they cause metabolic lipid and glucose effects even prior to weight gain (Teff et al. 2013) and possible progressive neurological issues”
BackgroundSelf-citationMetformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance
Remington, G. J., Teo, C., Wilson, V. S., Chintoh, A. F., Guenette, M. D., Ahsan, Z. A., Giacca, A., & Hahn, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0074 · Cited by 29
“…is growing evidence, both clinical and preclinical, indicating increased liability for glucose dysregulation independent of illness-related factors or weight increases (Ader et al. 2005, Houseknecht et al. 2007, Chintoh et al. 2009, Vidarsdottir et al. 2010a, Teff et al. 2013, Hahn et al. 2014).”
BackgroundMethodHuang, D., Gao, J., Li, C., Nong, C., Huang, W., Zheng, X., Li, S., & Peng, Y. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05878-9 · Cited by 29
Taylor, J. H., Jakubovski, E., Gabriel, D., & Bloch, M. H. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0147 · Cited by 27
“Moreover, discovering predictors and moderators of weight gain may yield insights into potential mechanisms of antipsychotic-related metabolic changes, which are poorly understood (Teff et al. 2013; Manu et al. 2015).”
BackgroundShamshoum, H., Medak, K. D., & Wright, D. C. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113049 · Cited by 32
Correll, C. U., Stein, E. A., Graham, C. E., DiPetrillo, L., Akerman, S. C., Stanford, A. D., Jiang, Y., Yagoda, S., McDonnell, D., & Hopkinson, C. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac144 · Cited by 28
Rosenbaum, S., Nijjar, S., Watkins, A., Garwood, N., Sherrington, C., & Tiedemann, A. (2014) · International Journal of Mental Health Nursing · doi:10.1111/inm.12057 · Cited by 26
“In addition, a recent and growing body of literature has identified the negative consequences of common psychotropic medications, resulting in further metabolic dysfunction and weight gain (Curtis et al. 2012; Teff et al. 2013).”
BackgroundHoirisch-Clapauch, S., & Nardi, A. E. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.011 · Cited by 26
“Hyperinsulinemia due to insulin resistance is a common side-effect of both conventional and atypical antipsychotics (Teff et al., 2013).”
BackgroundMorrison, A. P. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.010 · Cited by 31
Zaki, J. K., Lago, S. G., Rustogi, N., Gangadin, S. S., Benáček, J., van Rees, G. F., Haenisch, F., Broek, J. A. C., Suárez‐Pinilla, P., Ruland, T., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02229-w · Cited by 28
“This is consistent with the well-known effects that antipsychotic medications have on peripheral insulin signalling pathways [40].”
Antipsychotics impair regulation of glucose metabolism by central glucose
Castellani, L. N., Pereira, S., Kowalchuk, C., Asgariroozbehani, R., Singh, R., Wu, S., Hamel, L., Alganem, K., Ryan, W. G., Zhang, X., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01798-y · Cited by 29
Freyberg, Z., & Gittes, G. K. (2022) · Diabetes · doi:10.2337/db22-0522 · Cited by 24
Zajkowska, I., Niczyporuk, P., Urbaniak, A. D., Tomaszek, N., Modzelewski, S., & Waszkiewicz, N. (2024) · Nutrients · doi:10.3390/nu16142228 · Cited by 24
“The changes occur regardless of dietary mechanisms, as metabolic changes were seen in patients who showed no weight gain or increased food intake [236].”
BackgroundChong, J. W. X., Tan, E. H.-J., Chong, C. E., Ng, Y., & Wijesinghe, R. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.07.178 · Cited by 26
“It is important to note that more recent work suggests direct effects of AAPs on insulin-sensitive tissues mediated by mechanisms independent of regulating eating behavior or appetite, and in the absence of psychiatric disease, weight gain, food intake, or hunger.(35)”
Mechanism Underlying Induction of Hyperglycemia in Rats by Single Administration of Olanzapine
Nagata, M., Nakajima, M., Ishiwata, Y., Takahashi, Y., Takahashi, H., Negishi, K., & Yasuhara, M. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00842 · Cited by 24
Murray, R. M., Correll, C. U., Reynolds, G. P., & Taylor, D. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317693200 · Cited by 27
Wu, C., Yuen, J. W. Y., Boyda, H. N., Procyshyn, R. M., Wang, C. K., Asiri, Y. I., Pang, C. C. Y., Honer, W. G., & Barr, A. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107116 · Cited by 24
“Another recent study with non-psychiatric subjects used the hyperinsulinemic euglycemic clamp (HIEC) to show that treatment with olanzapine for nine days caused significant insulin resistance in the absence of weight gain, increases in food intake, or hunger [19].”
ResultPolygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives
Padmanabhan, J. L., Nanda, P., Tandon, N., Mothi, S. S., Bolo, N. R., McCarroll, S. A., Clementz, B. A., Gershon, E. S., Pearlson, G. D., Sweeney, J. A., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.02.015 · Cited by 25
“, 2014), insulin release (Teff et al., 2013), glucose transport (Dwyer et al.”
BackgroundToledo, F. G. S., Martin, W. F., Morrow, L., Beysen, C., Bajorunas, D. R., Jiang, Y., Silverman, B. L., McDonnell, D., Namchuk, M., Newcomer, J. W., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01244-7 · Cited by 22
“Olanzapine-induced hyperinsulinemia has been observed previously in studies of patients with schizophrenia [32, 33] and healthy volunteers [30, 34].”
BackgroundAdipokine levels are associated with insulin resistance in antipsychotics users independently of BMI
Vedal, T. S. J., Steen, N. E., Birkeland, K. I., Dieset, I., Reponen, E. J., Laskemoen, J. F., Rødevand, L. N., Melle, I. S., Andreassen, O. A., Molden, E., et al. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.01.001 · Cited by 22
“, 2008), findings of induced insulin resistance with aripiprazole (Teff et al., 2013) and induced expression of leptin and adiponectin in adipocytes from aripiprazole (Sarvari et al.”
Happell, B., Platania‐Phung, C., Bocking, J., Ewart, S. B., Scholz, B., & Stanton, R. (2018) · Journal of Interprofessional Care · doi:10.1080/13561820.2018.1516201 · Cited by 22
“Atypical antipsychotics are primarily prescribed for the treatment of psychosis, they differ from traditional drug therapy in having less extrapyramidal side effects (Foley & Morley, 2011; Teff et al., 2013).”
BackgroundAn Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
Citrome, L., Graham, C. E., Simmons, A., Jiang, Y., Todtenkopf, M. S., Silverman, B. L., DiPetrillo, L., Cummings, H., Sun, L., & McDonnell, D. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s313840 · Cited by 24
Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients
Ebdrup, B. H., Knop, F. K., Madsen, A., Mortensen, H. B., Søgaard, B., Holst, J. J., Szecsi, P. B., & Lublin, H. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08820 · Cited by 21
Horská, K., Kučerová, J., Dražanová, E., Karpíšek, M., Demlová, R., Kašpárek, T., & Kotolová, H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.003 · Cited by 22
“Interestingly, in healthy human subjects short-term (9 days) olanzapine administration led to dysregulation of postprandial GLP-1, but not leptin or ghrelin, whereas no similar effect was seen with ARI (Teff et al., 2013).”
BackgroundAntipsychotic Drugs and Dysregulated Glucose Homeostasis: A Systematic Review and Meta-Analysis
Smith, E. C. C., Agarwal, S. M., Panganiban, K. J., Maksyutynska, K., Monteiro, J., Lee, J., Prasad, F., Ji, A., Shah, D., Cavalier, S., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2240 · Cited by 21
Singh, R., Bansal, Y., Sodhi, R. K., Khare, P., Bishnoi, M., Kondepudi, K. K., Medhi, B., & Kuhad, A. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115124 · Cited by 20
Vochosková, K., McWhinney, S. R., Fialová, M., Kolenič, M., Španiel, F., Švancer, P., Boron, P., Okaji, Y., Trančík, P., & Hájek, T. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13594 · Cited by 19
Rarinca, V., Vasile, A., Visternicu, M., Burlui, V., Halitchi, G., Ciobica, A. S., Sîngeap, A.-M., Dobrin, R., Burlui, E., Maftei, L., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1497569 · Cited by 20
Chen, H., Cao, T., Zhang, B., & Cai, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1097284 · Cited by 18
“, 2015), GLP-1 (Teff et al., 2013), and 5-HT (Sohn et al.”
Burghardt, K. J., Mando, W., Seyoum, B., Yi, Z., & Burghardt, P. R. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2689 · Cited by 18
Ersland, K. M., Skrede, S., Røst, T. H., Berge, R. K., & Steen, V. M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115602490 · Cited by 18
“This finding supports our previous reports that lipogenic gene expression is not secondary to antipsychotic-induced weight gain, in agreement with clinical demonstration of weight-independent adverse metabolic effects of antipsychotic agents (Albaugh et al., 2011; Teff et al., 2013).”
ResultRickels, M. R., Perez, E. M., Peleckis, A. J., Al-Shehabi, E., Nguyen, H.-L., Stefanovski, D., Rickels, K., & Teff, K. L. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2017 · Cited by 19
“In the present study, trends were observed for increased postprandial pancreatic polypeptide and GIP responses consistent with previously reported increases in postprandial glucagon and GLP-1 in our previous study (26).”
BackgroundMethodResultSelf-citationMutwalli, H., Keeler, J. L., Bektas, S., Dhopatkar, N., Treasure, J. L., & Himmerich, H. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.006 · Cited by 20
“…(n = 7) (Ballon et al., 2018; Blouin et al., 2008; Fountaine et al., 2010; Gothelf et al., 2002; Okamoto et al., 2019; Roerig et al., 2005; Teff et al., 2013) or by using standardized tools such as the Food Frequency Questionnaire, 24-h dietary recall or built-in software such as the…”
BackgroundMethodChronically Increased Levels of Circulating Insulin Secondary to Insulin Resistance: A Silent Killer
Fazio, S., Bellavite, P., & Affuso, F. (2024) · Biomedicines · doi:10.3390/biomedicines12102416 · Cited by 18
“Also, atypical antipsychotics can induce insulin resistance and postprandial hormonal dysregulation independently from weight gain [18].”
BackgroundZhang, X., Zhao, Y., Liu, Y., Yuan, Y., Shao, H., & Zheng, X. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.001 · Cited by 17
Metadata
- Authors
- Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K.
- Affiliations
- Monell Chemical Senses Center (US)
- University of Pennsylvania (US)
- Corresponding author
- Teff, Karen L.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-08-15
- Volume
- 62
- Issue
- 9
- Pages
- 3232-3240
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3749337
- OpenAlex
- W2126815601
- Cited by
- 195
- References
- 51
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 14 · 2023: 10 · 2022: 14 · 2021: 15 · 2020: 12 · 2019: 12 · 2018: 21 · 2017: 15 · 2016: 18 · 2015: 19 · 2014: 15 · 2013: 5
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Pennsylvania
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 19525, R01DK084383, DK084383, P30DK019525)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- atypical antipsychotics, insulin resistance, olanzapine, aripiprazole, postprandial insulin, glucagon-like peptide-1, glucagon, glucose disposal, insulin sensitivity, metabolic side effects, weight gain, appetite, hyperinsulinemic-euglycemic clamp, meal challenge
- MeSH terms
- Aripiprazole, Olanzapine, Adult, Mental Disorders, Benzodiazepines, Eating, Female, Humans, Insulin Resistance, Male, Piperazines, Antipsychotic Agents, Quinolones, Weight Gain, Postprandial Period, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.